

IN THE CLAIMS:

Claims 9 and 19 were previously canceled without prejudice or disclaimer. Claim 8 is canceled herein, again without prejudice or disclaimer. All of the pending claims 1 through 7, 10 through 18, and 20 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of Claims:

1. (Previously presented) A method for treating an NFkappaB regulated inflammatory condition comprising administering to a subject in need of such treatment a molecule consisting of an oligopeptide selected from Table 6 or functional analogue thereof, said molecule capable of reducing production of NO by a cell.
2. (Previously presented) A method for treating an NFkappaB regulated inflammatory condition comprising administering to a subject in need of such treatment a molecule consisting of an oligopeptide selected from Table 6 or functional analogue thereof wherein said molecule is capable of modulating translocation and/or activity of a gene transcription factor present in a cell.
3. (Original) The method according to claim 1 wherein said molecule additionally is capable of modulating translocation and/or activity of a gene transcription factor present in said cell.
4. (Previously presented) The method according to claim 2 wherein said gene transcription factor comprises a NF-kappaB/Rel protein.
5. (Original) The method according to claim 3 wherein said modulating translocation and/or activity of a gene transcription factor allows modulation of TNF-alpha production by said cell.

6. (Original) The method according to claim 5 wherein said TNF-alpha production is reduced.
7. (Previously presented) The method according to claim 1 wherein said inflammatory condition comprises an acute inflammatory condition.
8. (Canceled).
- 9 (Canceled).
10. (Previously presented) The method according to claim 1 wherein said treatment comprises administering to said subject a pharmaceutical composition comprising the molecule capable of reducing production of NO by a cell.
11. (Original) The method according to claim 10 wherein said pharmaceutical composition comprises at least two oligopeptides or functional analogues thereof capable of reducing production of NO by a cell.
12. (Original) The method according to claim 11 wherein said at least two oligopeptides are selected from the group consisting of LQGV (SEQ ID NO:1), AQGV (SEQ ID NO:2) and VLPALP (SEQ ID NO:3).
13. (Withdrawn) An isolated oligopeptide or functional analogue thereof capable of reducing production of NO by a cell.
14. (Withdrawn) A pharmaceutical composition comprising an oligopeptide or functional analogue according to claim 13.

15. (Withdrawn) The pharmaceutical composition of claim 14 comprising at least two oligopeptides or functional analogues thereof capable of reducing production of NO by said cell.

16. (Previously presented) A method of treating an NFkappaB regulated inflammatory condition in a subject by reducing NO production by the subject's macrophages, the method comprising administering to the subject an oligopeptide selected from Table 6 or functional analogue thereof capable of reducing production of NO by a cell.

17. (Previously presented) The method according to claim 3 wherein said gene transcription factor comprises a NF-kappaB/Rel protein.

18. (Previously presented) The method according to claim 2 wherein said inflammatory condition comprises an acute inflammatory condition.

19. (Canceled).

20. (Previously presented) The method according to claim 2 wherein said treatment comprises administering to said subject a pharmaceutical composition comprising the molecule capable of reducing production of NO by a cell.